Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra

Movement Disorders

Volumn 28, Issue 10, 2013, Pages 1351-1359

  Reyes, Stefanie ^a   Cottam, Veronica ^a   Kirik, Deniz ^b   Double, Kay L ^a   Halliday, Glenda M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Dopamine receptors; Impulse control disorders; Parkinson's disease; Substantia nigra; Ventral tegmental area

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; PEROXIDASE; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER;

AGED; ARTICLE; BRAIN STEM; DOPAMINERGIC NERVE CELL; FEMALE; GENETIC VARIABILITY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMPULSIVENESS; MALE; MESENCEPHALON; NERVE CELL; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

DOPAMINE RECEPTORS; IMPULSE CONTROL DISORDERS; PARKINSON'S DISEASE; SUBSTANTIA NIGRA; VENTRAL TEGMENTAL AREA;

AGED; AGED, 80 AND OVER; BRAIN CHEMISTRY; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOHISTOCHEMISTRY; IMPULSE CONTROL DISORDERS; MALE; MESENCEPHALON; RECEPTORS, DOPAMINE; SUBSTANTIA NIGRA; VENTRAL TEGMENTAL AREA;

EID: 84884716311     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25493     Document Type: Article

References (56)

1. Evans AH, Strafella AP, Weintraub D, Stacy M. Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord. 2009;24:1561-1570.
2. Voon V, Dalley JW. Parkinson disease: impulsive choice-Parkinson disease and dopaminergic therapy. Nat Rev Neurol. 2011;7:541-542.
3. Kelley BJ, Duker AP, Chiu P. Dopamine agonists and pathologic behaviors. Parkinson Dis. 2012;2012:603631.
4. Villa C, Pascual-Sedano B, Pagonabarraga J, Kulisevsky J. Impulse control disorders and dopaminergic treatments in Parkinson's disease. Rev Neurol (Paris). 2011;167:827-832.
5. Voon V, Mehta AR, Hallett M. Impulse control disorders in Parkinson's disease: recent advances. Curr Opin Neurol. 2011;24:324-330.
6. Ford CP, Gantz SC, Phillips PE, Williams JT. Control of extracellular dopamine at dendrite and axon terminals. J Neurosci. 2010;30:6975-6983.
7. Buckholtz JW, Treadway MT, Cowan RL, et al. Dopaminergic network differences in human impulsivity. Science. 2010;329:532.
8. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114:2283-2301.
9. McRitchie DA, Cartwright HR, Halliday GM. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease. Exp Neurol. 1997;144:202-213.
10. Ray N, Miyasaki JM, Zurowski M, et al. Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: A [11C] FLB-457 and PET study. Neurobiol Dis. 2012;48:519-525.
11. Hurd YL, Pristupa ZB, Herman MM, Niznik HB, Kleinman JE. The dopamine transporter and dopamine D2 receptor messenger RNAs are differentially expressed in limbic- and motor-related subpopulations of human mesencephalic neurons. Neuroscience. 1994;63:357-362.
12. Haber SN, Ryoo H, Cox C, Lu W. Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity. J Comp Neurol. 1995;362:400-410.
13. Ciliax BJ, Drash GW, Staley JK, et al. Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol. 1999;409:38-56.
14. Miller GW, Staley JK, Heilman CJ, Perez JT, Mash DC, Rye DB, et al. Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann Neurol. 1997;41:530-539.
15. Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev. 2004;56:331-349.
16. Nicola SM, Surmeier J, Malenka RC. Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annu Rev Neurosci. 2000;23:185-215.
17. Jang JY, Jang M, Kim SH, et al. Regulation of dopaminergic neuron firing by heterogeneous dopamine autoreceptors in the substantia nigra pars compacta. J Neurochem. 2011;116:966-974.
18. Hurley MJ, Mash DC, Jenner P. Dopamine D(1) receptor expression in human basal ganglia and changes in Parkinson's disease. Brain Res Mol Brain Res. 2001;87:271-279.
19. De Keyser J, De Backer JP, Vauquelin G, Ebinger G. D1 and D2 dopamine receptors in human substantia nigra: localization and the effect of aging. J Neurochem. 1991;56:1130-1133.
20. Khan ZU, Gutierrez A, Martin R, Penafiel A, Rivera A, de la Calle A. Dopamine D5 receptors of rat and human brain. Neuroscience. 2000;100:689-699.
21. De Keyser J, Claeys A, De Backer JP, Ebinger G, Roels F, Vauquelin G. Autoradiographic localization of D1 and D2 dopamine receptors in the human brain. Neurosci Lett. 1988;91:142-147.
22. Palacios JM, Camps M, Cortes R, Probst A. Mapping dopamine receptors in the human brain. J Neural Transm Suppl. 1988;27:227-235.
23. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev. 1998;78:189-225.
24. Bonci A, Hopf FW. The dopamine D2 receptor: new surprises from an old friend. Neuron. 2005;47:335-338.
25. Mercuri NB, Calabresi P, Bernardi G. The electrophysiological actions of dopamine and dopaminergic drugs on neurons of the substantia nigra pars compacta and ventral tegmental area. Life Sci. 1992;51:711-718.
26. Adell A, Artigas F. The somatodendritic release of dopamine in the ventral tegmental area and its regulation by afferent transmitter systems. Neurosci Biobehav Rev. 2004;28:415-431.
27. Matsumoto M, Hikosaka O. Two types of dopamine neuron distinctly convey positive and negative motivational signals. Nature. 2009;459:837-841.
28. McRitchie DA, Hardman CD, Halliday GM. Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans. J Comp Neurol. 1996;364:121-150.
29. Halliday G, Reyes S, Double K. Substantia nigra, ventral tegmental area and retrorubral fields. In: Mai J, Paxinos G, eds. The Human Nervous System. 3rd ed. London: Elseveir; 2012.
30. Reyes S, Fu Y, Double K, et al. GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. J Comp Neurol. 2012:520:2591-2607.
31. Hahn J, Kullmann PH, Horn JP, Levitan ES. D2 autoreceptors chronically enhance dopamine neuron pacemaker activity. J Neurosci. 2006;26:5240-5247.
32. Diaz J, Pilon C, Le Foll B, Gros C, Triller A, Schwartz JC, et al. Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J Neurosci. 2000;20:8677-8684.
33. De Keyser J, De Backer JP, Vauquelin G, Ebinger G. D1 and D2 dopamine receptors in human substantia nigra: localization and the effect of aging. J Neurochem. 1991;56:1130-1133.
34. Liang CL, Nelson O, Yazdani U, Pasbakhsh P, German DC. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons. J Comp Neurol. 2004;473:97-106.
35. Gonzalez-Hernandez T, Barroso-Chinea P, De La Cruz Muros I, Del Mar Perez-Delgado M, Rodriguez M. Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons. J Comp Neurol. 2004;479:198-215.
36. Afonso-Oramas D, Cruz-Muros I, Alvarez de la Rosa D, et al. Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease. Neurobiol Dis. 2009;36:494-508.
37. Zald DH, Cowan RL, Riccardi P, et al. Midbrain dopamine receptor availability is inversely associated with novelty-seeking traits in humans. J Neurosci. 2008;28:14372-14378.
38. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain. 1999;122:1437-1448.
39. Halliday GM, McRitchie DA, Cartwright H, Pamphlett R, Hely MA, Morris JG. Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease. J Clin Neurosci. 1996;3:52-60.
40. Ikemoto S. Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res Rev. 2007;56:27-78.
41. Chen BT, Rice ME. Synaptic regulation of somatodendritic dopamine release by glutamate and GABA differs between substantia nigra and ventral tegmental area. J Neurochem. 2002;81:158-169.
42. Wolfart J, Neuhoff H, Franz O, Roeper J. Differential expression of the small-conductance, calcium-activated potassium channel SK3 is critical for pacemaker control in dopaminergic midbrain neurons. J Neurosci. 2001;21:3443-3456.
43. Bostwick JM, Hecksel KA, Stevens SR, Bower JH, Ahlskog JE. Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. Mayo Clin Proc. 2009;84:310-316.
44. Hassan A, Bower JH, Kumar N, et al. Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies. Parkinsonism Relat Disord. 2011;17:260-264.
45. Gallagher DA, O'Sullivan SS, Evans AH, Lees AJ, Schrag A. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord. 2007;22:1757-1763.
46. Cilia R, Ko JH, Cho SS, et al. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. Neurobiol Dis. 2010;39:98-104.
47. Rao H, Mamikonyan E, Detre JA, et al. Decreased ventral striatal activity with impulse control disorders in Parkinson's disease. Mov Disord. 2010;25:1660-1669.
48. Voon V, Reynolds B, Brezing C, et al. Impulsive choice and response in dopamine agonist-related impulse control behaviors. Psychopharmacology. 2010;207:645-659.
49. Cilia R, Cho SS, van Eimeren T, et al. Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: a path modeling analysis. Mov Disord. 2011;26:225-233.
50. Gibb WR, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1991;54:388-396.
51. Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature. 1988;334:345-348.
52. Yamada T, McGeer PL, Baimbridge KG, McGeer EG. Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res. 1990;526:303-307.
53. Lundblad M, Decressac M, Mattsson B, Bjorklund A. Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc Natl Acad Sci U S A. 2012;109:3213-3219.
54. Swant J, Goodwin JS, North A, et al. alpha-Synuclein stimulates a dopamine transporter-dependent chloride current and modulates the activity of the transporter. J Biol Chem. 2011;286:43933-43943.
55. Bannon MJ, Poosch MS, Xia Y, Goebel DJ, Cassin B, Kapatos G. Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age. Proc Natl Acad Sci U S A. 1992;89:7095-7099.
56. Haycock JW, Becker L, Ang L, Furukawa Y, Hornykiewicz O, Kish SJ. Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. J Neurochem. 2003;87:574-585.